

## FOREWORD

Lymphomas represent a very fast-growing field for both researchers and clinicians. The knowledge on the genetics and biology keeps on increasing. We can now subdivide the different histotypes in molecularly defined subgroups. A multitude of genes have been identified that, when deregulated, support the survival and growth of the lymphoma cells in a direct manner or indirectly influencing the tumor microenvironment. Targeted agents as single agents and in combination are used in the clinical practice and are evaluated in multiple clinical trials. Finally, improvements in imaging technologies and molecular analyses on cell-free DNA have been providing the rationale to adapt treatment plans based on the speed and depth of response.

This book touches all these aspects with specific chapters. The first three chapters discuss certain specific lymphoma conditions: the pediatric lymphomas, the EBV-related lymphomas, and the immunodeficiency-related lymphomas in patients treated with immunosuppressive drugs for autoimmune disease or conditions other than in the post-transplant setting. The chapters describe the genetics, the diagnostics, and the clinical features. These disease-focused works are accompanied by a chapter on SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase), one of the most interesting proteins deregulated in lymphoma for its role in chromatin remodeling and transcription regulation. The second part of the book starts with a chapter summarizing the type of information that can now be obtained with  $^{18}\text{F}$ -fluoro-deoxy-glucose positron emission tomography/computed tomography ( $^{18}\text{F}$ FDG-PET/CT) scans done before, during and after treatment, better defining the prognosis of patients and their response to treatment. This is nicely followed by a comprehensive overview of the management of patients with Hodgkin lymphoma, discussing the changes brought by the introduction of  $^{18}\text{F}$ FDG-PET/CT in this disease, of the anti-CD30 antibody-drug conjugate brentuximab vedotin and of the immune checkpoint inhibitors. The last chapter discusses the not always easy access to PET/CT in the non-Western world due to financial and educational issues. This book will be of value to healthcare professionals caring for individuals with lymphomas, researchers involved in lymphoma research, and those who are interested in gaining knowledge on lymphomas.

Prof. Francesco Bertoni  
Institute of Oncology Research,  
Faculty of Biomedical Sciences, USI,  
Bellinzona, Switzerland

Doi: <https://doi.org/10.36255/exon-publications.lymphoma.2021.Foreword>

